Jiangxi Sanxin Medtec Co Ltd (300453) - Net Assets
Based on the latest financial reports, Jiangxi Sanxin Medtec Co Ltd (300453) has net assets worth CN¥1.62 Billion CNY (≈ $236.90 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.44 Billion ≈ $357.62 Million USD) and total liabilities (CN¥824.99 Million ≈ $120.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Jiangxi Sanxin Medtec Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.62 Billion |
| % of Total Assets | 66.24% |
| Annual Growth Rate | 19.9% |
| 5-Year Change | 58.72% |
| 10-Year Change | 181.13% |
| Growth Volatility | 26.42 |
Jiangxi Sanxin Medtec Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Jiangxi Sanxin Medtec Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300453 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jiangxi Sanxin Medtec Co Ltd (2011–2025)
The table below shows the annual net assets of Jiangxi Sanxin Medtec Co Ltd from 2011 to 2025. For live valuation and market cap data, see Jiangxi Sanxin Medtec Co Ltd (300453) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.55 Billion ≈ $227.34 Million |
+10.29% |
| 2024-12-31 | CN¥1.41 Billion ≈ $206.13 Million |
+5.60% |
| 2023-12-31 | CN¥1.33 Billion ≈ $195.20 Million |
+15.45% |
| 2022-12-31 | CN¥1.16 Billion ≈ $169.07 Million |
+18.04% |
| 2021-12-31 | CN¥978.79 Million ≈ $143.23 Million |
+15.80% |
| 2020-12-31 | CN¥845.23 Million ≈ $123.68 Million |
+17.72% |
| 2019-12-31 | CN¥718.02 Million ≈ $105.07 Million |
+17.65% |
| 2018-12-31 | CN¥610.32 Million ≈ $89.31 Million |
+4.90% |
| 2017-12-31 | CN¥581.81 Million ≈ $85.14 Million |
+5.28% |
| 2016-12-31 | CN¥552.62 Million ≈ $80.87 Million |
+3.90% |
| 2015-12-31 | CN¥531.87 Million ≈ $77.83 Million |
+112.52% |
| 2014-12-31 | CN¥250.27 Million ≈ $36.62 Million |
+20.55% |
| 2013-12-31 | CN¥207.61 Million ≈ $30.38 Million |
+30.60% |
| 2012-12-31 | CN¥158.96 Million ≈ $23.26 Million |
+29.85% |
| 2011-12-31 | CN¥122.42 Million ≈ $17.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangxi Sanxin Medtec Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2969.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥735.36 Million | 50.43% |
| Other Components | CN¥722.93 Million | 49.57% |
| Total Equity | CN¥1.46 Billion | 100.00% |
Jiangxi Sanxin Medtec Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangxi Sanxin Medtec Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
$718.49 Million |
|
Formosa International Hotels Corp
TW:2707
|
$718.49 Million |
|
Banco do Estado do Rio Grande do Sul S.A
SA:BRSR3
|
$718.64 Million |
|
Minerva S.A
SA:BEEF3
|
$718.82 Million |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
$718.13 Million |
|
Zhejiang Mtcn Technology Co Ltd
SHE:003026
|
$718.10 Million |
|
HELL.UNSP.ADR A1 DL-0001
F:1MO
|
$718.04 Million |
|
Gujarat State Fertilizers & Chemicals Limited
NSE:GSFC
|
$718.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangxi Sanxin Medtec Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,324,065,860 to 1,458,293,542, a change of 134,227,682 (10.1%).
- Net income of 262,489,300 contributed positively to equity growth.
- Dividend payments of 163,286,855 reduced retained earnings.
- Other comprehensive income decreased equity by 131,332,058.
- Other factors increased equity by 166,357,295.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥262.49 Million | +18.0% |
| Dividends Paid | CN¥163.29 Million | -11.2% |
| Other Comprehensive Income | CN¥-131.33 Million | -9.01% |
| Other Changes | CN¥166.36 Million | +11.41% |
| Total Change | CN¥- | 10.14% |
Book Value vs Market Value Analysis
This analysis compares Jiangxi Sanxin Medtec Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 28.45x to 3.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.33 | CN¥9.40 | x |
| 2012-12-31 | CN¥0.41 | CN¥9.40 | x |
| 2013-12-31 | CN¥0.56 | CN¥9.40 | x |
| 2014-12-31 | CN¥0.68 | CN¥9.40 | x |
| 2015-12-31 | CN¥1.12 | CN¥9.40 | x |
| 2016-12-31 | CN¥1.11 | CN¥9.40 | x |
| 2017-12-31 | CN¥1.18 | CN¥9.40 | x |
| 2018-12-31 | CN¥1.21 | CN¥9.40 | x |
| 2019-12-31 | CN¥1.28 | CN¥9.40 | x |
| 2020-12-31 | CN¥1.52 | CN¥9.40 | x |
| 2021-12-31 | CN¥1.76 | CN¥9.40 | x |
| 2022-12-31 | CN¥2.09 | CN¥9.40 | x |
| 2023-12-31 | CN¥2.40 | CN¥9.40 | x |
| 2024-12-31 | CN¥2.57 | CN¥9.40 | x |
| 2025-12-31 | CN¥2.82 | CN¥9.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangxi Sanxin Medtec Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.00%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.00%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.67x
- Recent ROE (18.00%) is above the historical average (16.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 28.61% | 15.89% | 1.10x | 1.63x | CN¥22.78 Million |
| 2012 | 30.01% | 17.01% | 1.05x | 1.68x | CN¥31.80 Million |
| 2013 | 23.43% | 15.96% | 0.92x | 1.59x | CN¥27.88 Million |
| 2014 | 19.43% | 15.09% | 0.84x | 1.52x | CN¥23.59 Million |
| 2015 | 9.75% | 16.64% | 0.53x | 1.11x | CN¥-1.31 Million |
| 2016 | 6.63% | 11.52% | 0.51x | 1.13x | CN¥-18.65 Million |
| 2017 | 7.32% | 10.50% | 0.60x | 1.16x | CN¥-15.52 Million |
| 2018 | 6.79% | 7.74% | 0.64x | 1.37x | CN¥-19.46 Million |
| 2019 | 9.22% | 8.55% | 0.63x | 1.71x | CN¥-5.23 Million |
| 2020 | 14.73% | 12.30% | 0.76x | 1.59x | CN¥37.11 Million |
| 2021 | 17.22% | 13.39% | 0.83x | 1.55x | CN¥65.36 Million |
| 2022 | 17.16% | 13.82% | 0.75x | 1.66x | CN¥77.02 Million |
| 2023 | 16.58% | 15.89% | 0.64x | 1.63x | CN¥81.99 Million |
| 2024 | 17.17% | 15.16% | 0.68x | 1.68x | CN¥95.00 Million |
| 2025 | 18.00% | 16.00% | 0.68x | 1.67x | CN¥116.66 Million |
Industry Comparison
This section compares Jiangxi Sanxin Medtec Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $3,379,853,522
- Average return on equity (ROE) among peers: 18.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangxi Sanxin Medtec Co Ltd (300453) | CN¥1.62 Billion | 28.61% | 0.51x | $718.14 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.13 Billion | 7.47% | 2.10x | $467.27 Million |
| Blue Sail Medical Co Ltd (002382) | $916.68 Million | 3.17% | 0.43x | $825.68 Million |
| Andon Health Co Ltd (002432) | $20.02 Billion | 80.05% | 0.09x | $5.00 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $909.99 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $281.42 Million |
| QITIAN Technology Group Co Ltd (300061) | $471.02 Million | -17.67% | 1.36x | $722.27 Million |
| Shanghai Tofflon Science Tech (300171) | $2.95 Billion | 13.12% | 0.38x | $1.27 Billion |
| Truking Technology Ltd (300358) | $31.38 Million | 49.25% | 3.63x | $842.36 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $553.38 Million | 7.13% | 0.22x | $1.31 Billion |
About Jiangxi Sanxin Medtec Co Ltd
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. The company offers infusion and cardiothoracic surgery products; and blood purification products, such as dialysate filter, dialysis indwelling needle, disposable biological protein glue dispenser, dialysis fluid filter, continuous blood purification pipeline and accessories,… Read more